Form 4: Kymera Therapeutics Director Sells Shares

Kymera Therapeutics Director Bruce Booth reported the sale of company stock totaling over 27,000 shares through a Rule 10b5-1 trading plan.

Summary

• Bruce Booth, a Director at Kymera Therapeutics, Inc., reported transactions involving the sale of common stock on June 29, 2026.
• These sales were executed under a Rule 10b5-1 trading plan adopted on December 11, 2025.
• The total number of shares sold across various transactions on June 29, 2026, amounts to 27,588.
• The sales involved weighted average prices ranging from $108.03 to $111.63 per share.
• Following these transactions, Booth's beneficial ownership of Kymera Therapeutics common stock is reported as indirect.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant sale of shares by a director, even though it was conducted under a pre-arranged plan.

Negatives

• Director Bruce Booth sold a significant number of shares (27,588) on June 29, 2026.
• The sales were conducted under a pre-arranged trading plan, indicating a planned divestment of shares.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which primarily reports past transactions.

Industry Context

StockSavvy.ai notes that insider sales, especially those under Rule 10b5-1 plans, are common for executives and directors to diversify holdings or manage personal finances. The volume and timing relative to stock performance are key factors for investors to consider.

Stakeholder Impact

• Shareholders may view the director's sale of stock as a potential signal, although the Rule 10b5-1 plan mitigates concerns about insider trading based on non-public information.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Director Transaction, Beneficial Ownership